Peptide / Unit conversion

PT-141 reconstitution calculator

Enter your PT-141 vial size, the volume of liquid added and the dose to calculate concentration and syringe units.

Your inputs determine the result. This calculator does not recommend dosages.

Live readout

Set your draw.

Enter your vial strength, diluent, and dose to see the draw.

Mode
Resulting concentration -- mg/mL
Doses per vial --
Syringe

Conversion follows standard mg, mL, and U-100 syringe references.

Performs unit conversions only. Not medical advice. Consult your healthcare provider.

Save preset

After saving, open Presets at the top of the calculator to recall this setup.

Saved presets

No saved presets

Save a conversion from the calculator to recall it later.

    Units chart

    PT-141 units chart (mg to U-100 units)

    PT-141 units chart: mg to U-100 units

    PT-141 appears in PinPoint as the generic compound bremelanotide, a melanocortin receptor agonist. It is an FDA-approved medicine as a single-dose autoinjector; the 10 mg vial here is an example input. Five vial fractions provide the amount-to-units comparisons here.

    Vial concentration

    Water mL is treated as final solution mL in these columns.

    PT-141: concentration in mg per mL
    Vial contents1 mL water2 mL water3 mL water
    10 mg10 mg/mL10 U-100 units per mg5 mg/mL20 U-100 units per mg3.3333 mg/mL30 U-100 units per mg

    Example vial size (input): 10 mg. No source is cited for this size; it is an arithmetic input, not a sourced fact.

    Amount to units

    Example amounts (arithmetic only, not doses).

    PT-141: amount to U-100 syringe units
    Amount (mg)10 mg + 1 mL10 mg + 2 mL10 mg + 3 mL
    0.2 mg2 units4 units6 units
    0.5 mg5 units10 units15 units
    1 mg10 units20 units30 units
    2 mg20 units40 units60 units
    5 mg50 units100 units150 unitsover one syringe

    The label's amount

    The label's presentation is a single-dose prefilled autoinjector containing 1.75 mg of bremelanotide in 0.3 mL; no approved bremelanotide product comes as a vial.

    PT-141: the label's amounts as its dosage section states them
    Amount (mg) and source contextFrequency as statedRoute as statedVolume as statedSource
    1.75 mgLabel amount for premenopausal women with acquired, generalized HSDD; at most 8 doses in a month. As needed, at least 45 minutes before sexual activity; at most once per 24 hours and 8 times monthlySubcutaneous0.3 mL, the whole single-dose autoinjector Bremelanotide prescribing informationRegulatory labelRetrieved 2026-11-19

    How to read this chart

    units = amount ÷ (vial mg ÷ water mL) × 100

    The reconstitution calculator walks through each step, and units to mg converts between mg, mcg, mL and units.

    Peak timing in an event log

    The label reports a median time to peak of about 1 hour and absolute bioavailability of about 100% after subcutaneous injection by autoinjector. The event's timestamp is what places the modeled rise on the log's timeline. An amount recorded at one clock time and the same amount recorded hours later produce differently positioned estimates even though their concentration and syringe-volume arithmetic can be identical.

    Frequency text without a repeating weekly pattern

    The PT-141 frequency labels in the app, As needed and Not more than once in 24h, follow the label's directions rather than a recurring weekday interval. This makes the actual sequence of logged timestamps especially useful when reviewing the record. The chart does not infer a weekly total from those labels; it presents individual mg amounts and their corresponding liquid volumes.

    An example vial expressed in portions

    The 10 mg figure is an example input for the arithmetic; no approved bremelanotide product comes as a vial. Its example rows are 0.2, 0.5, 1, 2, and 5 mg. Consider the 1 mg portion: it is a tenth of the vial's contents, so its volume is a tenth of each column's solution volume. That gives 0.1, 0.2, and 0.3 mL, or 10, 20, and 30 U-100 units. The half-vial row of 5 mg follows the same relationship but reaches 1.5 mL in the final column.

    Compound profile

    PT-141 at a glance

    Bremelanotide (development code PT-141) is a melanocortin receptor agonist.[2][1] It is FDA-approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder. The label's reference values are a half-life of about 2.7 hours, a median time to peak of about 1 hour and absolute bioavailability of about 100%.

    Regulatory status
    Bremelanotide is an FDA-approved prescription medicine (first US approval 2019) for premenopausal women with acquired, generalized hypoactive sexual desire disorder, approved as a single-dose 1.75 mg autoinjector.[1]
    Half-life
    About 2.7 hours (range 1.9 to 4.0 hours) after a single subcutaneous dose, per the label.[1]
    Route
    Subcutaneous, by autoinjector, per the label.[1]
    Category
    Peptide
    Label schedule
    As needed, at least 45 minutes before anticipated sexual activity; not more than one dose within 24 hours, per the label.[1]
    Vial size
    10 mg, example vial size (input)

    The label gives a half-life of about 2.7 hours. The 10 mg figure is an example input for the arithmetic; no approved bremelanotide product comes as a vial.[1]

    Evidence

    What the research says

    The bremelanotide label describes two controlled phase 3 studies in premenopausal women with acquired, generalized hypoactive sexual desire disorder. Participants received subcutaneous bremelanotide or placebo during a 24-week controlled phase. The research population and indication are narrower than a general claim about sexual function.[1]

    The primary assessments used patient-reported measures of desire and associated distress. The studies also collected adverse-event information and included an open-label extension. These clinical assessments are distinct from the pharmacokinetic program, which measured plasma bremelanotide exposure after subcutaneous administration.[1]

    The label reports concentration and exposure parameters for its formulated autoinjector product. The example research vial in the library is a separate record and is not the studied device. Product identity, route, population, and measured endpoint all remain necessary context for reading the bremelanotide evidence.[1]

    Timing

    Half-life and timing

    About 2.7 hours (range 1.9 to 4.0 hours) after a single subcutaneous dose, per the label.[1]

    Calculator details

    About this calculation.

    Does a PT-141 calculator reproduce the approved product?

    A calculator does not reproduce an approved device. Arithmetic does not establish formulation equivalence or replace the approved presentation instructions.

    Does the PT-141 vial calculator include the approved device's instructions?

    No. It does not reproduce a device model or select an administration amount. The calculator link remains a separate arithmetic resource; an unverified example vial size cannot supply verified preparation inputs.

    What concentration is PT-141 at 10 mg in 1 mL?

    10 mg divided by 1 mL is 10 mg per mL. That volume spans 100 U-100 syringe units.

    How does 2 mL change the concentration of this PT-141 vial?

    10 mg divided by 2 mL is 5 mg per mL, half the concentration in the 1 mL column.

    What does the 3 mL column mean for PT-141?

    10 mg divided by 3 mL is approximately 3.3333 mg per mL. The full 3 mL volume corresponds to 300 U-100 units.

    How many units is 1 mg of PT-141 from this vial in 2 mL?

    1 mg divided by 5 mg per mL is 0.2 mL, or 20 U-100 units.

    References

    Sources

    Sources checked against the cited documents on 19 November 2026.

    1. Bremelanotide injection, prescribing information (DailyMed, SPL effective 5 November 2026)Read 19 November 2026: Highlights (initial US approval 2019), 1, 2 dosage and administration, 6.1, 11, 12.1, 12.3, 14, 16.Retrieved 2026-11-19 · label
    2. Bremelanotide and blood pressure in premenopausal women, 2017 (PubMed 27977473; open-access full text PMC5338879)Full text: its references describe intranasal and subcutaneous PT-141, tying the development code to bremelanotide.Retrieved 2026-11-19 · human-study
    3. PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description

    From the same library

    Related calculators

    Keep your protocol together

    Track the result in the app.

    Set up vials, log doses and sites, and see your next reminder in PinPoint for iOS.

    Download on the App Store
    Syringe readout: 10 units is 0.10 mL on a U-100 insulin syringe
    THE ARITHMETIC / 0.10 mL = 10 UNITS

    Keep exploring

    More tools

    PinPoint app icon

    Your next chapter starts here

    Start Day 1 with
    your numbers in place.

    Your doses, your schedule, your picture. Bring it together in PinPoint.

    Built for iPhone.

    Subscription through the App Store, cancel anytime in your Apple ID settings.